Similarly, in the Beat-AML cohort, patients with high BATF expression and low EGR1 expression had the shortest OS (3-year OS: 18.18% vs. 46.15% and 69.92%, P < 0.001) (Figure 2C). This evidence concerns the gene BATF and acute myeloid leukemia.